Our observations that P2X3 agonist 2-MeSATP treatment alone was sufficient to induce cyclin D3 expression (1.9 fold) and pre-treatment with an alternative P2X3 antagonist, A317491 attenuated ATP induced cyclin D3 expression in Huh7 cells further validates the role of P2X3 purinergic receptor activation in the induction of cell-cycle progression in HCC cells (Figure 5C & 5D) [32-34]. Here, P2RX3 is linked to hepatocellular carcinoma.